Geneva, Apr 22 (EFE).- Swiss pharmaceutical giant Roche said Tuesday that it will invest $50 billion in pharmaceutical and diagnostics manufacturing facilities in the United States over the next five years, creating over 12,000 jobs.
The announcement comes amid rising trade tensions, including the new US tariff threats that could also affect Swiss companies.
The investment will fund the construction and expansion of factories and research centers in several US states, the Basel-based company said in a statement.
"These investments further strengthen Roche's already significant US footprint (.) and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities," the company said.
Roche currently employs 25,000 people across 15 research and development (R&D) sites and 13 manufacturing facilities in eight US states.
As part of the new investment, Roche plans to open a gene therapy plant in Pennsylvania and an AI-driven R&D center in Massachusetts, focusing on cardiovascular, kidney, and metabolic diseases.
Once the new projects are completed, Roche expects to "export more medicines from the US than it imports."
"We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US," said Roche Group CEO Thomas Schinecker.
US President Donald Trump has threatened to impose a 31 percent tariff, currently on hold for 90 days, on imports from Switzerland, a move that could affect the country's influential pharmaceutical sector.
Roche's announcement follows a similar move by fellow Swiss drugmaker Novartis, which recently unveiled plans to invest $23 billion to build and expand 10 facilities in the US over the next five years. EFE
© 2025 EFE News Services (U.S.) Inc., source EFE Ingles
